We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Normal Cells and Cancer Cells Differentiated by Degree of Protein Phosphorylation

By LabMedica International staff writers
Posted on 09 Dec 2009
Print article
Cancer researchers have developed a method to differentiate cancer and normal cells at the molecular level based on different degrees of protein phosphorylation.

At the molecular level, cancers are heterogeneous diseases, arising from genetic factors, environmental carcinogens, and random, somatic mutation. Phosphorylation of proteins is a key regulator of protein activity, and in particular, modification of tyrosine residues modulates critical signaling and control processes. In cancers, aberrant phosphorylation status of key residues (its presence or absence) has been observed and documented in many studies.

Investigators at Boston University (MA, USA) collaborated with specialists at Cell Signaling Technology (Danvers, MA, USA) in order to apply the "Phosphoscan" methodology to establish a comparative profile of the phosphorylation properties of proteins in normal and cancer cells.

They reported in the November 25, 2009, issue of the journal PLoS ONE that a large set of sites were differentially phosphorylated in tumors, many of which can be used as direct targets for new drugs. Furthermore they employed a novel computational approach to perform a protein variant of gene set enrichment analysis that showed that certain pathways were differentially activated, based on their global phosphorylation status. A relatively small number of phosphorylated peptides observed in that data could discriminate between normal tissue and tumors with a high degree of sensitivity and specificity.

"Identifying the phosphorylation status of proteins in cancer cells versus normal cells provides us with a unique ability to understand and perhaps intervene with the command and control center of cancer cells," said contributing author Dr. Simon Kasif, professor of biomedical engineering at Boston University. "Drugs are most effective on cancers when they attack the proteins that are activated."

Related Links:
Boston University
Cell Signaling Technology


New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.